instruction:
Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.
question:
Paragraph: Speaking at a White House coronavirus briefing, Trump said he would unveil a new advisory group next week that would focus on the process of economic opening. The president, who faced criticism for playing down the threat from the virus in its early stages, has chafed at the devastating economic impact of the strict social distancing measures his administration has recommended. The guidelines are set to stay in place through the end of April. The president will then have to decide whether to extend them or start encouraging people to go back to work and a more normal way of life. “I’m going to have to make a decision, and I ... hope to God that it’s the right decision,” Trump said. “It’s the biggest decision I’ve ever had to make.”  Trump said the facts would determine the next move, though he reiterated his desire to re-open the economy. Asked what metrics he would use to make his judgment, he pointed at his forehead: “The metrics right here, that’s my metrics.”  Trump suggested the number of new infections was flattening and the death toll would be lower than initial projections of more than 100,000. He said he would announce the members of the new advisory council possibly on Tuesday. Some state governors will be appointed. Trump said the aggressive social distancing and stay-at-home measures taken to combat the coronavirus were showing signs of success, and situations in hot spots such as New Orleans, Louisiana, and Detroit, Michigan, were stabilizing. U.S. deaths from the virus topped 18,100 on Friday, according to a Reuters tally. But administration officials cautioned it was still too early to ease restrictions, and said the faithful should not gather in churches on the Easter Sunday holiday. “We know it’s difficult in this time of year in particular to avoid gatherings of more than 10, but we’re grateful that so many churches, synagogues and places of worship have done just that,” Vice President Mike Pence said, urging worshipers “to continue to heed the guidelines.”  New U.S. government figures show coronavirus infections will spike during the summer if stay-at-home orders are lifted after 30 days as planned, according to projections first reported by the New York Times and confirmed by a Department of Homeland Security official. If shelter-in-place orders are lifted after 30 days, the death toll is estimated to reach 200,000, according to the projections, obtained from DHS and the Department of Health and Human Services. Trump said at the briefing that he and his advisers have not seen the new projections. Trump said he was getting fewer calls from governors urgently seeking equipment and help. “We’re in great shape with ventilators, we’re in great shape with protective clothing, we have additional planeloads coming in. But we’re not getting any calls from governors at this moment,” he said. Dr. Deborah Birx, the coordinator of the White House task force on the coronavirus, said the United States was starting to flatten the curve the way Italy did, with a lot of the success coming from progress in New York City. Officials have pointed to declining rates of coronavirus hospitalizations and need for intensive care in hard-hit New York as signs that social distancing measures are paying off. “But as encouraging as they are, we have not reached the peak. And so every day we need to continue to do what we did yesterday, and the week before and the week before that because that’s what in the end is going to take us across the peak and down the other side,” Birx said. Claim: Using his own 'metrics,' Trump says ending U.S. shutdown is biggest decision yet.
answer:
President Donald Trump said on Friday he faced his biggest decision yet with regard to when to re-open the U.S. economy from its coronavirus shutdown and pledged to listen to health experts when making that determination.


question:
Paragraph: The Wuhan Municipal Health Commission said seven other people were in critical condition among a total of 41 who were suffering from pneumonia caused by a “preliminarily determined new type of coronavirus” as of Friday. That was down from the earlier figure of 59. The others were in stable condition and at least two had been released from a hospital. The patient who died was identified as a 61-year-old man who had been hospitalized after suffering shortness of breath and severe pneumonia. The commission said the man, who died Thursday, also suffered from abdominal tumors and chronic liver disease and had been a frequent customer at a food market on Wuhan’s outskirts linked to the majority of cases. China says the cause of the Wuhan outbreak remains unknown, but has sought to quash speculation that it could be a reappearance of the SARS epidemic, which killed hundreds in 2002 and 2003. Coronaviruses are a large family of viruses, some of which cause the common cold. Others found in bats, camels and other animals have evolved into more severe illnesses. Common symptoms include a runny nose, headache, cough and fever. Shortness of breath, chills and body aches are associated with more dangerous kinds of coronaviruses, according to the U.S. Centers for Disease Control and Prevention. China’s transport ministry says it plans additional measures to disinfect trains, planes and buses and prevent transmission of diseases during the 40-day travel rush centered on the Lunar New Year, also known as the Spring Festival, which falls this year on Jan. 25. The period began Friday and runs through Feb. 18. “The emergence of the epidemic may cause panic among people, especially in areas where people are concentrated during the Spring Festival travel period,” the ministry’s chief engineer, Wang Yang, told reporters at a news conference Thursday. “In order to further ensure the health of passengers, our ministry attaches great importance to the arrangements and deployment, and will focus on the disinfection monitoring and protection measures in areas with a large number of passenger travel volume, including transportation hubs, passenger stations and cargo hub plant stations,” Wang said. Possible cases of the same illness have been reported in Hong Kong, South Korea and Taiwan involving recent travelers to Wuhan. Health authorities elsewhere in China have yet to announce similar cases, despite the high population density around Wuhan and its role as a travel hub for central China. University of Hong Kong disease expert Yuen Kwok-yung was quoted by the city’s official news agency as saying that the genetic makeup of the novel coronavirus was 80% similar to SARS as it had been found in bats, civet cats and humans. Yuen said that it was unclear whether the virus could further change to become more lethal, as the SARS virus had, but that Hong Kong had a robust system for detecting more severe problems among patients. “So we have to take every measure and closely monitor the situation,” Yuen said, according to Radio Television Hong Kong. Claim: China reports 1st death from new type of coronavirus .
answer:
Health authorities in a central Chinese city on Saturday reported the country’s first death from a new type of coronavirus, as the government braced for the Lunar New Year travel boom amid concerns over a possible outbreak similar to that of the SARS virus in the early 2000s.


question:
Paragraph: The release, while loaded with information about the research, fails to mention costs related to this new approach at any point. This is in spite of the fact that the paper provides what’s necessary to fulfill this criterion. The study authors wrote: “The easy access to the tumor site, the absence of the need for surgical removal of the tissue containing the T cells, the numbers of cells obtained with the harvest, and the ability to expand products in all patients with a relatively short process at a reasonable cost contrast sharply with several limitations of TIL ACT” (a current therapeutic approach to the disease). The release does a good job of spelling out the results of this phase 1 trial by providing data showing that MILs can target and kill cancer cells. It shows that in more than half of the study’s patients, their cancers had shrunk by at least half. In 15 of the 22 patients, their cancers did not progress for nearly a year after the MILs therapy. This wasn’t a controlled study, so it’s unclear how these patients would have fared without the MILs treatment, and the release could have attempted to provide some insight on that point. But we’re pleased that the release focuses appropriately on the apparent safety of the approach, rather than trying to make claims about survival benefits that aren’t supportable by this kind of small, uncontrolled study. The release also explains that the research provides information suggesting which patients might benefit best from this approach, and that other research at this cancer center is centered on testing this approach on different forms of cancer. We’ll give this criterion a satisfactory rating since the release specifically spells out, “None of the participants had serious side effects from the MILs therapy.” However, the study is really too small, and the time span too short, to comment substantively on the possible harms that might be seen if and when the treatment is more widely used. The research paper actually makes the point that the new procedure doesn’t require the “surgical removal of tissue,” and the procedure can be done at bedside rather than an operating suite. But the removal of cells from the bone marrow is still an invasive procedure that carries its own risk of infection or other problems. The release would have benefited from at least mentioning this aspect. The release makes a very good effort to objectively describe a technically complicated trial. It defines the trial at least twice as being “small” and calls it a “pilot,” suggesting that caution is appropriate when considering the results. It effectively explains the process involved in the treatments, including what was learned regarding the growth of cells in the lab after harvesting. It also points to the fact that while tumor-infiltrating lymphocytes (TILs) can only be retrieved from a quarter of the patient candidates for this technique, MILs were obtained from all of the patients in this study, suggesting that they may be a better tool for this therapy. Describing multiple myeloma as “the second most common cancer originating in the blood” doesn’t add much to our understanding of this disease. However, other statistics provide context regarding the scope of the problem in the United States. We’ll give it a pass. The funding sources for this research are listed in an end note in the release. No conflict of interest information is provided in the release, although the research paper discloses no conflicts. The release does mention that other forms of this adoptive T cell therapy use different cells, suggesting that other approaches are possible. The release also notes, “Three days before the injections of expanded MILs, patients received high doses of chemotherapy and a stem cell transplant, standard treatments for multiple myeloma.” The release points out that “several U.S. cancer centers have conducted similar experimental treatments” but adds that Johns Hopkins is the only one using the MIL cells. It also points to several other ongoing clinical trials at Hopkins that build on the findings of this small study. Using the terms “pilot” and “experimental,” the release signals that availability is very limited. We like the fact that the headline itself defines this as a “pilot” clinical trial and that the lede says that it is “what is believed to be the first small clinical trial of its kind.”  Those kinds of qualifiers both declare the specifics of the research and also provide informative caveats, allowing the reader to gauge how much credence to give to the findings. All too many other medical releases fail to provide this measured approach. This release is conservative throughout in its choice of language in describing this research which, based on its findings, might be ripe for exaggeration. Claim: Pilot clinical trial finds injected immune cells safe in multiple myeloma patients
answer:

This is a report of a phase I clinical trial testing whether specific immune cells harvested from the bone marrow, grown in the lab and then re-infused into multiple myeloma patients can effectively change the immune environment in the patient and suggest a possibly improved disease outcome. It looks at using a different population of immune cells — marrow-infiltrating lymphocytes (MILs) — from those used in previous studies. These are both easier to retrieve and easier to grow in the lab, two factors that reduce the complexity of this treatment approach. The release is in many ways a model for other organizations reporting on similar studies. The description of the study is clear, the language used appropriately conservative, and there is context regarding the novelty of the approach and current alternative treatments. Some discussion of possible costs — preliminary though it would have to be — would have completed the picture for readers. Rather than hyping such a study in a frenzied attempt to attract clicks and eyeballs, Hopkins presents the findings in a thoughtful way that reflects well on the institution’s reputation and will help build that reputation over the long haul. Multiple myeloma is one of several cancers of the blood and the National Cancer Institute estimates that nearly 27,000 new cases of myeloma will be diagnosed this year. Less than half of patients live as much as five years after their diagnosis, and more than 11,000 patients are expected to die from the disease this year. Any new approach to treating this and other blood cancers stands to benefit the nearly 90,000 patients now living with this disease in the U.S.